MD Anderson start-up leveraging MD Anderson’s unique proprietary cancer patient tissue bank, clinical database and surfaceome expertise to identify novel oncology targets for solid tumors. Three novel targets, each with several large indications, are in pre-clinical development with the first IND expected in 2027.